Category:



  • 20Aug

    LOS ANGELES, Aug. 20 /PRNewswire-USNewswire/ — For CIOs, Chief Knowledge Officers, researchers and other professionals managing knowledge assets for their organization, the Southern California Knowledge Management Forum (http://bschool.pepperdine.edu/newsevents/kmforum/) will be held September 9-11, 2008 in Malibu, CA, at Pepperdine University (http://bschool.pepperdine.edu/welcome/locations/malibu.html). By managing the processes, information systems, corporate culture, and expertise that exists at all levels and locations of the business, a company can discard processes that don’t work, encourage the adoption of those that do, and anticipate, rather than react to, problem situations. The three-day event explores best practices from social networks, Web 2.0 and the multi-generational workforce that are shaping the evolution of knowledge for value creation by such global leaders as Apple, Google, Pratt & Whitney Rocketdyne Inc, Northrop Grumman Corporation, NASA, Fluor Corporation, Xerox and The Walt Disney Company.

    The conference program (http://bschool.pepperdine.edu/newsevents/kmforum/schedule.html) will cover these vital topics:
    – How social and communication networks contribute to knowledge sharing and knowledge management
    – Implications of Web 2.0 for enhancing enterprise collaboration opportunities
    – Obstacles to knowledge sharing across generations
    – Web 2.0 strategies for increased innovation and productivity
    – Impact of “age diversity” on the workplace and generational commonalities that cut across racial, ethnic, and economic differences
    – Knowledge mining lessons from the past to secure future success
    – Project development and execution for knowledge management

    Notable keynote speakers (http://bschool.pepperdine.edu/newsevents/kmforum/speakers08.html) include:
    – Randy Adkins, Director, U.S. Air Force Knowledge Management Center of Excellence
    – Stephen Cranford, Managing Director, PricewaterhouseCoopers
    – Vijay Koduri, Product Marketing Manager, Google Inc.
    – Scott Koziol, Higher Education Account Executive, Apple Inc.
    – Dan Nerison, Manager of Knowledge Community Deployment and Performance, Fluor Corporation
    – Christina Ramstein, Director of Intelligence and Collaboration, The Walt Disney Company
    – Tom Soderstrom, Chief Information Officer, NASA-JPL
    – Captain Ralph Soule, Commanding Officer, United States Navy Team Carrier One

    Hosted by Pepperdine University’s Graziadio School of Business and Management, Second Annual Southern California Knowledge Management Forum will provide comprehensive interactive discussions, case studies and networking opportunities intended to build a community of best practices across industries on knowledge management topics, strategies and innovations.

    Visit http://bschool.pepperdine.edu/newsevents/kmforum/ for more information and to register.

    About the Graziadio School of Business and Management
    Founded on the core values of integrity, stewardship, courage, and compassion, Pepperdine University’s Graziadio School of Business and Management (http://bschool.pepperdine.edu) has been developing values-centered leaders for contemporary business practice since 1969. Our portfolio of fully accredited MBA, Master of Science and bachelor’s completion business degree programs provide personalized attention in an intimate setting, emphasis on applied and relevant business practices, and the convenience of six campus locations throughout Southern California. With an alumni network of more than 30,000 business professionals, the Graziadio School delivers superior flexibility, quality of experience and depth of knowledge for professionals continuing their education as full-time students, fully-employed degree recipients and senior executives.

    Contact:
    Douglass Gore, Director of Public Relations
    Phone: (310) 568-5580
    GraziadioPR@pepperdine.edu

    SOURCE Pepperdine University Graziadio School of Business

  • 19Aug

    CHARLOTTE, N.C., Aug. 19 /PRNewswire-FirstCall/ — Wachovia Corporation
    (NYSE: WB) announced that its board of directors has declared dividends on
    three series of preferred stock.

    A quarterly cash dividend of $20 per share was declared on its 8.00% non-
    cumulative perpetual class A preferred stock, Series J, liquidation preference
    $1,000 per share. This dividend equals $0.50 per depositary share, each
    representing a 1/40th interest in a share of Series J preferred stock, which
    are traded on the New York Stock Exchange under the symbol “WBPRS.” The
    Series J dividend is payable on September 15, 2008, to holders of record as of
    the close of business on August 29, 2008.

    A quarterly cash dividend of $18.75 per share was declared on its 7.50%
    non-cumulative perpetual convertible class A preferred stock, Series L,
    liquidation preference $1,000 per share, which are traded on the New York
    Stock Exchange under the symbol “WBPRT”. The Series L dividend is payable on
    September 15, 2008, to holders of record as of the close of business on August
    29, 2008.

    In addition, a semi-annual cash dividend of $48.10167 per share was
    declared on its Fixed-to-Floating Rate non-cumulative perpetual Class A
    preferred stock, Series K, liquidation preference $1,000 per share. This
    payment represents the dividend accrued from the Series K issuance on February
    8, 2008 to but excluding September 15, 2008. The Series K dividend is payable
    on September 15, 2008, to holders of record as of the close of business on
    August 29, 2008.

    About Wachovia

    Wachovia Corporation (NYSE: WB) is one of the nation’s largest diversified
    financial services companies, with assets of $812.4 billion and market
    capitalization of $33.5 billion at June 30, 2008. Wachovia provides a broad
    range of retail banking and brokerage, asset and wealth management, and
    corporate and investment banking products and services to customers through
    3,300 retail financial centers in 21 states from Connecticut to Florida and
    west to Texas and California, and nationwide retail brokerage, mortgage
    lending and auto finance businesses. Globally, clients are served in selected
    corporate and institutional sectors and through more than 40 international
    offices. Our retail brokerage operations under the Wachovia Securities brand
    name manage more than $1.1 trillion in client assets through 14,600 financial
    advisors in 1,500 offices nationwide. Online banking is available at
    wachovia.com; online brokerage products and services at wachoviasec.com; and
    investment products and services at evergreeninvestments.com.

    SOURCE Wachovia Corporation

  • 19Aug

    DURHAM, N.C., Aug. 19 /PRNewswire/ — Addrenex Pharmaceuticals
    ( http://www.addrenex.com ) has made three strategic hires this month to
    further its goal of identifying and developing as many new drug candidates as
    possible over the next 18 months.

    The fast-paced timeline they have set for drug discovery mirrors the
    company’s recent successes in developing two new drugs, Clonicel(R) for
    attention deficit/hyperactivity disorder and CloniBID for hypertension, over
    the past two years. A new drug application has already been filed for
    CloniBID, with Food and Drug Administration review expected by December 2008,
    and Clonicel is in phase 3 clinical trials. Commercial rights to both drugs
    have been granted to Atlanta-based Sciele Pharma.

    The additions of Steven Butts, M.B.A., as vice president of commercial
    operations and Gary Bream, Ph.D., as senior director of scientific affairs
    will strengthen Addrenex’s ability to pursue additional drugs to treat
    conditions such as menopausal flushing, pain, addiction, aggression, and post
    traumatic stress disorder, said Moise Khayrallah, Ph.D., cofounder and chief
    executive officer of Addrenex. Yuki Prescott has also joined as clinical
    trials manager and will enhance the clinical team’s ability to oversee a
    growing clinical program.

    “We now have a solid partnership in place with Sciele that will enable us
    to develop our lead compounds and to pursue additional compounds in our
    portfolio that target the alpha-2 adrenergic receptors,” said Khayrallah.
    “We’re using our lead compounds to power the rest of the portfolio. The highly
    skilled team we have now assembled gives us the capability to deliver on our
    commitments and meet our fast-paced timelines.”

    The indications being targeted by Addrenex are each associated with an
    overactive adrenergic system, a group of hormones produced by the adrenal
    glands that regulate the body’s reaction to stress, hormonal fluctuations and
    myriad environmental factors.

    To identify new drug candidates, Addrenex will delve into its vast library
    of 400 adrenergic compounds, housed at the University of Nebraska Medical
    Center. Addrenex licensed the rights to the portfolio in December, and the
    company has already produced a new drug candidate-ADX415-from the portfolio.
    The new compound will be developed for the treatment of hypertension and other
    potential indications.

    Bream will work with University of Nebraska scientists to further analyze
    various compounds for their affinity to alpha-2 adrenergic receptors and
    subreceptors that might enhance efficacy or reduce side effects of current
    alpha-2 compounds. He will be responsible for advancing several drug
    candidates through the preclinical and early clinical phases.

    Butts will work in tandem with the scientific group to identify
    indications where Addrenex can fill an unmet medical need, Khayrallah said.
    His expertise in commercializing drugs will help prioritize the most viable
    drug candidates in the pipeline. Butts will also oversee commercial efforts in
    the company’s current and future partnerships.

    “The convergence of commercial and scientific expertise is essential to
    optimizing our portfolio of drugs,” said Khayrallah. “We’re now in a position
    to carefully assess which compounds and which receptors are the best targets
    for addressing a desired indication.”

    Gary Bream

    Gary Bream brings to Addrenex a decade of regulatory affairs experience
    and 11 years of clinical research experience. Bream most recently served as
    senior director of regulatory affairs and strategic drug development services
    at Constella Group. He also served in the areas of regulatory affairs,
    clinical operations and clinical research at Constella, formerly Lineberry
    Research Associates and now SRA International. Bream’s career includes
    scientific positions at Merck Research Laboratories in West Point, PA, and at
    Burroughs Wellcome in Research Triangle Park, NC. Bream holds a doctorate in
    molecular biology from the University of California at Berkeley.

    Steven Butts

    Steven Butts has 13 years of experience in the pharmaceutical industry,
    having held leadership positions in marketing and brand management, sales, new
    product planning and business development at Eli Lilly and Company, Glaxo
    Wellcome and Braintree Laboratories. He was the U.S. marketing director of
    Lilly’s ADHD medication Strattera(R), leading the product from phase 2
    clinical trials through its second year in market. Butts joined Addrenex from
    Biobehavioral Diagnostics in Boston, where he served as vice president of
    marketing and sales. He holds a Master of Business Administration from the
    Kenan-Flagler Business School at the University of North Carolina at Chapel
    Hill.

    Yuki Prescott

    Yuki Prescott came to Addrenex from Constella Group, where she served as
    project manager and clinical research associate. In her early career, Prescott
    was a practicing physical therapist in both inpatient and outpatient settings.
    She has a master’s degree in physical therapy from East Carolina University
    and a bachelor’s degree in biology from Binghamton University in Binghamton,
    NY.

    SOURCE Addrenex Pharmaceuticals

  • 19Aug

    DURHAM, N.C., Aug. 19 /PRNewswire/ — Addrenex Pharmaceuticals
    ( http://www.addrenex.com ) has made three strategic hires this month to
    further its goal of identifying and developing as many new drug candidates as
    possible over the next 18 months.

    The fast-paced timeline they have set for drug discovery mirrors the
    company’s recent successes in developing two new drugs, Clonicel(R) for
    attention deficit/hyperactivity disorder and CloniBID for hypertension, over
    the past two years. A new drug application has already been filed for
    CloniBID, with Food and Drug Administration review expected by December 2008,
    and Clonicel is in phase 3 clinical trials. Commercial rights to both drugs
    have been granted to Atlanta-based Sciele Pharma.

    The additions of Steven Butts, M.B.A., as vice president of commercial
    operations and Gary Bream, Ph.D., as senior director of scientific affairs
    will strengthen Addrenex’s ability to pursue additional drugs to treat
    conditions such as menopausal flushing, pain, addiction, aggression, and post
    traumatic stress disorder, said Moise Khayrallah, Ph.D., cofounder and chief
    executive officer of Addrenex. Yuki Prescott has also joined as clinical
    trials manager and will enhance the clinical team’s ability to oversee a
    growing clinical program.

    “We now have a solid partnership in place with Sciele that will enable us
    to develop our lead compounds and to pursue additional compounds in our
    portfolio that target the alpha-2 adrenergic receptors,” said Khayrallah.
    “We’re using our lead compounds to power the rest of the portfolio. The highly
    skilled team we have now assembled gives us the capability to deliver on our
    commitments and meet our fast-paced timelines.”

    The indications being targeted by Addrenex are each associated with an
    overactive adrenergic system, a group of hormones produced by the adrenal
    glands that regulate the body’s reaction to stress, hormonal fluctuations and
    myriad environmental factors.

    To identify new drug candidates, Addrenex will delve into its vast library
    of 400 adrenergic compounds, housed at the University of Nebraska Medical
    Center. Addrenex licensed the rights to the portfolio in December, and the
    company has already produced a new drug candidate-ADX415-from the portfolio.
    The new compound will be developed for the treatment of hypertension and other
    potential indications.

    Bream will work with University of Nebraska scientists to further analyze
    various compounds for their affinity to alpha-2 adrenergic receptors and
    subreceptors that might enhance efficacy or reduce side effects of current
    alpha-2 compounds. He will be responsible for advancing several drug
    candidates through the preclinical and early clinical phases.

    Butts will work in tandem with the scientific group to identify
    indications where Addrenex can fill an unmet medical need, Khayrallah said.
    His expertise in commercializing drugs will help prioritize the most viable
    drug candidates in the pipeline. Butts will also oversee commercial efforts in
    the company’s current and future partnerships.

    “The convergence of commercial and scientific expertise is essential to
    optimizing our portfolio of drugs,” said Khayrallah. “We’re now in a position
    to carefully assess which compounds and which receptors are the best targets
    for addressing a desired indication.”

    Gary Bream

    Gary Bream brings to Addrenex a decade of regulatory affairs experience
    and 11 years of clinical research experience. Bream most recently served as
    senior director of regulatory affairs and strategic drug development services
    at Constella Group. He also served in the areas of regulatory affairs,
    clinical operations and clinical research at Constella, formerly Lineberry
    Research Associates and now SRA International. Bream’s career includes
    scientific positions at Merck Research Laboratories in West Point, PA, and at
    Burroughs Wellcome in Research Triangle Park, NC. Bream holds a doctorate in
    molecular biology from the University of California at Berkeley.

    Steven Butts

    Steven Butts has 13 years of experience in the pharmaceutical industry,
    having held leadership positions in marketing and brand management, sales, new
    product planning and business development at Eli Lilly and Company, Glaxo
    Wellcome and Braintree Laboratories. He was the U.S. marketing director of
    Lilly’s ADHD medication Strattera(R), leading the product from phase 2
    clinical trials through its second year in market. Butts joined Addrenex from
    Biobehavioral Diagnostics in Boston, where he served as vice president of
    marketing and sales. He holds a Master of Business Administration from the
    Kenan-Flagler Business School at the University of North Carolina at Chapel
    Hill.

    Yuki Prescott

    Yuki Prescott came to Addrenex from Constella Group, where she served as
    project manager and clinical research associate. In her early career, Prescott
    was a practicing physical therapist in both inpatient and outpatient settings.
    She has a master’s degree in physical therapy from East Carolina University
    and a bachelor’s degree in biology from Binghamton University in Binghamton,
    NY.

    SOURCE Addrenex Pharmaceuticals

  • 19Aug

    In the news release, Consortium Formed to Expand Recycling Options for
    Bioplastics, issued earlier today by Primo Water Corporation over PR Newswire,
    we are advised by the company that the contact information for this release
    should read “Sona Rai of Porter Novelli, for Primo Water Corporation,
    +1-212-601-8450, Sona.Rai@porternovelli.com” rather than “Josiah McClellan of
    Porter Novelli, for Primo Water Corporation, +1-212-601-8284,
    josiah.mcclellan@porternovelli.com” as originally issued inadvertently.

    ——

    Consortium Formed to Expand Recycling Options for Bioplastics

    Brand Owners, Recyclers, Retailers, NGOs and Academia Help Launch Bioplastics Recycling Consortium

    WINSTON SALEM, N.C., Aug. 19 /PRNewswire/ — Primo Water Corporation,
    along with 19 other organizations, has launched a new group to address
    recycling opportunities with bioplastics — the Bioplastics Recycling
    Consortium. The Consortium’s mission is to develop an effective, efficient and
    economical recovery system and end markets for post-consumer bioplastic
    materials. In doing so, the multi-industry Consortium will help ensure that
    bioplastics fulfill their promise of being a fully renewable and truly
    sustainable material for manufacturers, retailers, waste management, and
    recycling companies and consumers interested in developing packaging materials
    that are better for our environment.

    Participants in the Consortium’s first meeting represented the waste and
    recycling industry, brand owners, retailers, academic and research
    institutions, and NGOs, an intentional effort to bring together an eclectic
    group that will provide a 360-degree perspective on bioplastics in the waste
    stream.

    “Packaging born of renewable material, then recycled and reused for new
    packaging is the ultimate definition of sustainability. The Bioplastics
    Recycling Consortium has great potential because it’s the first dedicated
    effort to bring together multiple links in the value chain to talk
    specifically about bioplastics life cycle,” said Tim Ronan, vice president of
    marketing for Primo To Go. Primo recently introduced the first nationally
    distributed single serve bottled water whose bottle is made from plant based
    Ingeo(TM) natural resin, not crude oil like other water bottles. “Now is the
    time to seize on the life cycle opportunities that non oil-based bioplastics
    offer, and to develop an efficient recycling system that enhances the
    sustainability of these products that are truly friendlier on our
    environment.”

    According to a study by the Freedonia Group, demand for bioplastics in the
    U.S. is expected to increase 20 percent per year through 2010. The study also
    projects that the greatest growth potential for bioplastics is in applications
    such as films, bottles and food service products.

    The participants in the first consortium meeting included the Association
    of Postconsumer Plastic Recyclers, Climate Neutral, NatureWorks LLC, Porter
    Novelli, Primo Water Corporation, U.S. EPA Office of Solid Waste, University
    of Florida Bill Hinkley Center for Solid and Hazardous Waste Management, and
    the Yale Office of Sustainability. The Bioplastics Recycling Consortium is
    currently scheduling its next meeting to take place during Fall 2008.

    About Primo Water Corporation

    Primo Water Corporation, a privately-held company based in Winston-Salem,
    North Carolina, manufactures, markets, and services mineral enriched bottled
    water that meets both the convenience consumers seek and the environmental
    benefits they desire. Today, three product lines make up Primo Water
    Corporation’s portfolio. The first, introduced in June of 2005, offers 3 and
    5 gallon Zero Waste bottles and an exchange program that rewards consumers for
    recycling their bottles for refills. The second, launched in April of 2008,
    is a new line of Energy Star rated and stylish water coolers. And the third
    is a single-serve bottled water, in a more-environmentally-friendly bottle
    made from plants, not crude oil. According to blind taste tests, three out of
    four consumers prefer Primo over the leading spring water and four out of five
    prefer Primo over tap water. To learn more, visit www.primowater.com.

    SOURCE Primo Water Corporation

« Previous Entries